Abstract
BackgroundTislelizumab, an anti-PD-1 monoclonal antibody, demonstrated efficacy as monotherapy in patients with previously treated PD-L1+ urothelial carcinoma (UC) during a phase 2 study (NCT04004221). Here, gene expression profiles correlating with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
